ADC Biosafety & QC Support | HyQure

Antibody-Drug Conjugate (ADC) Characterization

Biosafety, viral clearance, impurity-control, microbial, and release-support pathways for ADC-associated biologics programs.

Request a Quote Contact a Scientific Project Manager

Modality > Biologics > ADC Characterization Testing

Program Overview

ADC programs combine complex biologics processes with tightly controlled manufacturing and release requirements. HyQure supports ADC-associated biologics programs through the biosafety and QC elements that are clearly supported in HYQURE.pdf: viral clearance or inactivation validation for the antibody process, production-cell qualification, host-cell impurity and process-residue control, microbial safety, and later-stage release support.

Why HyQure - Advantages

Viral clearance support for the biologics process

ADC-associated antibody production may require the same viral clearance or inactivation validation logic used for other biologics programs.
Cell line and substrate qualification

Production cell lines and banks can be qualified through HyQure's cell-line characterization and related biosafety pathways.
Host-cell impurity and process-residue control

Residual DNA, HCP/HCD-related support, and microbial pathways form the main analytical message for ADC-associated processes on this page.
Release-support documentation

Later-stage QC, method transfer, and sponsor-facing documentation are described carefully without implying unsupported payload analytics.

Supported ADC-Related Testing Scope

Viral clearance / inactivation validation

Study design and execution for antibody-process steps where viral reduction evidence is required.
Cell line characterization

Identity, sterility, mycoplasma, adventitious-agent, and related qualification testing for the biologic-producing substrate.
Residual DNA / HCP / HCD support

Impurity-control pathways and QC kits that support process and release decisions for ADC-associated biologics workflows.
Microbial and lot release support

Mycoplasma, microbial testing, and lot-release pathways that support clinical or commercialization-related quality control.

Sample Types and Deliverables

Sample types

Production cell banks, upstream and downstream process samples, bulk antibody or conjugated materials, and release-support samples confirmed during scoping.

Key deliverables

Viral-clearance reports, cell-line characterization packages, impurity-test summaries, method-transfer documents where applicable, and CoA-ready QC outputs.

Scope alignment

Program-specific analytical requirements should be confirmed early whenever the requested work extends beyond supported biosafety, impurity, and QC-support pathways.

Related programs

ADC work should link back to the broader biologics, viral-clearance, cell-line, and lot-release service ecosystem.